Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies

Journal of the American Society of Hypertension

Volumn 3, Issue 4, 2009, Pages 245-259

  Ban, Kiwon ^a,b,d   Hui, Sonya ^a,b,d   Drucker, Daniel J ^a,b,c   Husain, Mansoor ^a,b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

diabetes mellitus; Glucagon like peptide 1 (GLP 1); insulin resistance; ischemia reperfusion injury

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ATRIAL NATRIURETIC FACTOR; BIGUANIDE; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [9-36]; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSIDASE INHIBITOR; INCRETIN; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ACUTE PANCREATITIS; APPETITE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; CORONARY BLOOD VESSEL; DIABETES MELLITUS; DIARRHEA; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; FLUID RETENTION; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; ISOLATED HEART; MESENTERIC ARTERY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; RHINORRHEA; SIDE EFFECT; SORE THROAT; STROKE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 67650747353     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2009.04.001     Document Type: Review

References (141)

1. Rother K.I. Diabetes treatment-bridging the divide. N Engl J Med 12 (2007) 1499-1501
2. Grobbee D.E. How to ADVANCE prevention of cardiovascular complications in type 2 diabetes. Metab Clin Exp 52 (2003) 24-28
3. Cowie C.C., Rust K.F., Byrd-Holt D.D., Eberhardt M.S., Flegal K.M., Engelgau M.M., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 29 (2006) 1263-1268
4. Milicevic Z., Raz I., Beattie S.D., Campaigne B.N., Sarwat S., Gromniak E., et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 31 (2008) S155-S160
5. Laing S.P., Swerdlow A.J., Slater S.D., Burden A.C., Morris A., Waugh N.R., et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46 (2003) 760-765
6. Retnakaran R., and Zinman B. Type 1 diabetes, hyperglycaemia, and the heart. Lancet 371 (2008) 1790-1799
7. Stolar M.W., and Chilton R.J. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 25 (2003) B4-B31
8. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
9. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
10. Laakso M. Hyperglycemia as a risk factor for cardiovascular disease in type 2 diabetes. Prim Care 26 (1999) 829-839
11. Haffner S.M. Impaired glucose tolerance, insulin resistance, and cardiovascular disease. Diabetes Med 14 (1997) S12-S18
12. Gerstein H.C. Glucose: a continuous risk factor for cardiovascular disease. Diabetes Med 14 (1997) S25-S31
13. Mazzone T., Chait A., and Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 371 (2008) 1800-1809
14. Levy D., Larson M.G., Vasan R.S., Kannel W.B., and Ho K.K. The progression from hypertension to congestive heart failure. JAMA 275 (1996) 1557-1562
15. Kaplan N.M., and Opie L.H. Controversies in hypertension. Lancet 367 (2006) 168-176
16. Freis E.D., and Papademetriou V. Current drug treatment and treatment patterns with antihypertensive drugs. Drugs 52 (1996) 1-16
17. Julius S. Coronary disease in hypertension: a new mosaic. J Hypertens Suppl 15 (1997) S3-S10
18. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
19. Lacy C.R., Suh D.C., Barone J.A., Bueno M., Moylan D., Swartz C., et al. Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting. Arch Intern Med 162 (2002) 468-473
20. Aronow H.D., Topol E.J., Roe M.T., Houghtaling P.L., Wolski K.E., Lincoff A.M., et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 357 (2001) 1063-1068
21. Fisman E.Z., Motro M., and Tenenbaum A. Non-insulin anti-diabetic therapy in cardiac patients: current problems and future prospects. Adv Cardiol 45 (2008) 154-170
22. Uwaifo G.I., and Ratner R.E. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol 99 (2007) 51B-567
23. Brady P.A., Al-Suwaidi J., Kopecky S.L., and Terzic A. Sulfonylureas and mortality in diabetic patients after myocardial infarction. Circulation 97 (1998) 709-710
24. Calvert J.W., Gundewar S., Jha S., Greer J.J., Bestermann W.H., Tian R., et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 57 (2008) 696-705
25. Couzin J. Drug safety. Heart attack risk overshadows a popular diabetes therapy. Science 316 (2007) 1550-1551
26. Davis B.J., Xie Z., Viollet B., and Zou M.H. Activation of the AMP-activated kinase by anti-diabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 55 (2006) 496-505
27. Garratt K.N., Brady P.A., Hassinger N.L., Grill D.E., Terzic A., and Holmes Jr. D.R. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33 (1999) 119-124
28. Home P.D., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., Jones N.P., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
29. Lautamaki R., Airaksinen K.E., Seppanen M., Toikka J., Luotolahti M., Ball E., et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes 54 (2005) 2787-2794
30. Liao Y., Takashima S., Zhao H., Asano Y., Shintani Y., Minamino T., et al. Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice. Cardiovasc Res 70 (2006) 107-116
31. Libby P., Maroko P.R., and Braunwald E. The effect of hypoglycemia on myocardial ischemic injury during acute experimental coronary artery occlusion. Circulation 51 (1975) 621-626
32. Nikolaidis L.A., Mankad S., Sokos G.G., Miske G., Shah A., Elahi D., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004) 962-965
33. Olsson J., Lindberg G., Gottsater M., Lindwall K., Sjostrand A., Tisell A., et al. Increased mortality in type 2 diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43 (2000) 558-560
34. Quast U., Stephan D., Bieger S., and Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 53 (2004) S156-S164
35. Sack M.N., and Yellon D.M. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol 41 (2003) 1404-1407
36. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., and Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12 (2006) 694-699
37. Krentz A.J., and Bailey C.J. Oral anti-diabetic agents: current role in type 2 diabetes mellitus. Drugs 65 (2005) 385-411
38. Ashcroft F.M. Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 28 (1996) 456-463
39. Kramer W., Muller G., and Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta cells. Horm Metab Res 28 (1996) 464-468
40. Evans J.M., Ogston S.A., Emslie-Smith A., and Morris A.D. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49 (2006) 930-936
41. Meier J.J., Deifuss S., Klamann A., Schmiegel W., and Nauck M.A. Influence of an anti-diabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp Clin Endocrinol Diabetes 111 (2003) 344-350
42. Gross G.J., and Auchampach J.A. Role of ATP-dependent potassium channels in myocardial ischaemia. Cardiovasc Res 26 (1992) 1011-1016
43. Lazdunski M. Ion channel effects of anti-diabetic sulfonylureas. Horm Metab Res 28 (1996) 488-495
44. Meier J.J., Gallwitz B., Schmidt W.E., Mugge A., and Nauck M.A. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. Heart (British Cardiac Society) 90 (2004) 9-12
45. Gribble F.M., and Reimann F. Pharmacological modulation of K(ATP) channels. Biochem Soc Trans 30 (2002) 333-339
46. Cole W.C., McPherson C.D., and Sontag D. ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ Res 69 (1991) 571-581
47. Cleveland Jr. J.C., Meldrum D.R., Cain B.S., Banerjee A., and Harken A.H. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 96 (1997) 29-32
48. Toombs C.F., McGee S., Johnston W.E., and Vinten-Johansen J. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia. Circulation 86 (1992) 986-994
49. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
50. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., and Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008) 1577-1589
51. Cheng A.Y., and Fantus I.G. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 172 (2005) 213-226
52. Sasali A., and Leahy J.L. Is metformin cardioprotective?. Diabetes Care 26 (2003) 243-244
53. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 854-865
54. Fisman E.Z., Tenenbaum A., Benderly M., Goldbourt U., Behar S., and Motro M. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 91 (1999) 195-202
55. Rao A.D., Kuhadiya N., Reynolds K., and Fonseca V.A. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies. Diabetes Care 31 (2008) 1672-1678
56. Fisman E.Z., Tenenbaum A., Motro M., and Adler Y. Oral anti-diabetic therapy in patients with heart disease. A cardiologic standpoint. Herz 29 (2004) 290-298
57. Lee A.J. Metformin in noninsulin-dependent diabetes mellitus. Pharmacotherapy 16 (1996) 327-351
58. Adams J.F., Clark J.S., Ireland J.T., Kesson C.M., and Watson W.S. Malabsorption of vitamin B12 and intrinsic factor secretion during biguanide therapy. Diabetologia 24 (1983) 16-18
59. McGuire D.K., and Inzucchi S.E. New drugs for the treatment of diabetes mellitus: part I: thiazolidinediones and their evolving cardiovascular implications. Circulation 117 (2008) 440-449
60. Irons B.K., Greene R.S., Mazzolini T.A., Edwards K.L., and Sleeper R.B. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy 26 (2006) 168-181
61. Martens F.M., Rabelink T.J., Op't Roodt J., de Koning E.J., and Visseren F.L. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J 27 (2006) 1605-1609
62. Rohatgi A., and McGuire D.K. Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes-update 2008. Cardiovasc Drugs Ther 22 (2008) 233-240
63. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
64. Cheng A.Y., and Fantus I.G. Thiazolidinedione-induced congestive heart failure. Ann Pharmacother 38 (2004) 817-820
65. Erdmann E., and Wilcox R.G. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 29 (2008) 12-20
66. Sarafidis P.A. Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. Fundam Clin Pharmacol 22 (2008) 247-264
67. Khanderia U., Pop-Busui R., and Eagle K.A. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Ann Pharmacother 42 (2008) 1466-1474
68. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
69. Psaty B.M., and Furberg C.D. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 357 (2007) 67-69
70. Hoogwerf B.J. Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. Cleve Clin J Med 75 (2008) 729-737
71. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131 (1999) 281-303
72. Gore M.O., and McGuire D.K. The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diab Vasc Dis Res 6 (2009) 53-55
73. Fox C.S., Coady S., Sorlie P.D., D'Agostino Sr. R.B., Pencina M.J., Vasan R.S., et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115 (2007) 1544-1550
74. Elrick H., Stimmler L., Hlad C.J., and Arai Y. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 24 (1964) 1076-1082
75. Matsuyama T., Komatsu R., Namba M., Watanabe N., Itoh H., and Tarui S. Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone. Diabetes Res Clin Pract 5 (1988) 281-284
76. Weir G.C., Mojsov S., Hendrick G.K., and Habener J.F. Glucagon-like peptide-1-(7-37) actions on endocrine pancreas. Diabetes 38 (1989) 338-342
77. Wettergren A., Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., and Holst J.J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38 (1993) 665-673
78. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M.B., Meeran K., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 (1996) 69-72
79. Meeran K., O'Shea D., Edwards C.M., Turton M.D., Heath M.M., Gunn I., et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140 (1999) 244-250
80. Davis Jr. H.R., Mullins D.E., Pines J.M., Hoos L.M., France C.F., Compton D.S., et al. Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats. Obes Res 6 (1998) 147-156
81. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141 (2000) 1936-1941
82. Larsen P.J., Fledelius C., Knudsen L.B., and Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50 (2001) 2530-2539
83. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
84. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
85. Defronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
86. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., and Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278 (2003) 471-478
87. Xu G., Stoffers D.A., Habener J.F., and Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
88. Abraham E.J., Leech C.A., Lin J.C., Zulewski H., and Habener J.F. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 143 (2002) 3152-3161
89. Hardikar A.A., Wang X.Y., Williams L.J., Kwok J., Wong R., Yao M., et al. Functional maturation of fetal porcine beta-cells by glucagon-like peptide-1 and cholecystokinin. Endocrinology 143 (2002) 3505-3514
90. Movassat J., Beattie G.M., Lopez A.D., and Hayek A. Exendin 4 up-regulates expression of PDX1 and hastens differentiation and maturation of human fetal pancreatic cells. J Clin Endocrinol Metab 87 (2002) 4775-4781
91. Tourrel C., Bailbe D., Meile M.-J., Kergoat M., and Portha B. Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50 (2001) 1562-1570
92. Perfetti R., Zhou J., Doyle M.E., and Egan J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141 (2000) 4600-4605
93. Stoffers D.A., Desai B.M., DeLeon D.D., and Simmons R.A. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 52 (2003) 734-740
94. Wang Q., and Brubaker P.L. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8-week-old db/db mice. Diabetologia 45 (2002) 1263-1273
95. Tourrel C., Bailbe D., Lacorne M., Meile M.J., Kergoat M., and Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51 (2002) 1443-1452
96. Hui H., Nourparvar A., Zhao X., and Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144 (2003) 1444-1455
97. Bell G.I., Sanchez-Pescador R., Laybourn P.J., and Najarian R.C. Exon duplication and divergence in the human preproglucagon gene. Nature 304 (1983) 368-371
98. Rocca A.S., and Brubaker P.L. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140 (1999) 1687-1694
99. Anini Y., Hansotia T., and Brubaker P.L. Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology 143 (2002) 2420-2426
100. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., and Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide-1 receptor are mediated through both glucagon-like peptide-1 receptor-dependent and -independent pathways. Circulation 117 (2008) 2340-2350
101. Baggio L., Kieffer T.J., and Drucker D.J. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology 141 (2000) 3703-3709
102. Kolligs F., Fehmann H.-C., Goke R., and Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin(9-39)amide. Diabetes 44 (1995) 16-19
103. Wang Z., Wang R.M., Owji A.A., Smith D.M., Ghatei M.A., and Bloom S.R. Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95 (1995) 417-421
104. D'alessio D.A., Vogel R., Prigeon R., Laschansky E., Koerker D., Eng J., et al. Elimination of the action of glucagon-like peptide-1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97 (1996) 133-138
105. Schirra J., Sturm K., Leicht P., Arnold R., Goke B., and Katschinski M. exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 101 (1998) 1421-1430
106. Edwards C.M., Todd J.F., Mahmoudi M., Wang Z., Wang R.M., Ghatei M.A., et al. Glucagon-like peptide-1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin(9-39). Diabetes 48 (1999) 86-93
107. Deacon C.F., Johnsen A.H., and Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80 (1995) 952-957
108. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. J Biol Chem 267 (1992) 7402-7405
109. Egan J.M., Clocquet A.R., and Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87 (2002) 1282-1290
110. Egan JM, Meneilly GS, Elahi D. Effects of one month bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003;284:E1072-9.
111. Garber A.J., and Sharma M.D. Update: vildagliptin for the treatment of type 2 diabetes. Expert Opin Investig Drugs 17 (2008) 105-113
112. Karasik A., Aschner P., Katzeff H., Davies M.J., and Stein P.P. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 24 (2008) 489-496
113. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110 (2004) 955-961
114. Sokos G.G., Bolukoglu H., German J., Hentosz T., Magovern Jr. G.J., Maher T.D., et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 100 (2007) 824-829
115. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., and Yellon D.M. Glucagon-like peptide-1 (GLP-1) can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 (2005) 146-151
116. Scrocchi L.A., Brown T.J., MacClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide-1 receptor gene. Nat Med 2 (1996) 1254-1258
117. Hansotia T., Baggio L.L., Delmeire D., Hinke S.A., Yamada Y., Tsukiyama K., et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-4 inhibitors. Diabetes 53 (2004) 1326-1335
118. De Leon D.D., Deng S., Madani R., Ahima R.S., Drucker D.J., and Stoffers D.A. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52 (2003) 365-371
119. Preitner F., Ibberson M., Franklin I., Binnert C., Pende M., Gjinovci A., et al. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 113 (2004) 635-645
120. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110 (2002) 43-52
121. Gros R., You X., Baggio L.L., Kabir M.G., Sadi A.M., Mungrue I.N., et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144 (2003) 2242-2252
122. Daniel E.E., Anvari M., Fox-Threlkeld J.E.T., and McDonald T.J. Local, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum. Am J Physiol Gastrointest Liver Physiol 283 (2002) G595-G602
123. Wang Y., Kole H.K., Montrose-Rafizadeh C., Perfetti R., Bernier M., and Egan J.M. Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions. J Mol Endocrinol 19 (1997) 241-248
124. Montrose-Rafizadeh C., Yang H., Rodgers B.D., Beday A., Pritchette L.A., and Eng J. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem 272 (1997) 21201-21206
125. Nikolaidis L.A., Elahi D., Shen Y.T., and Shannon R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289 (2005) H2401-H2408
126. Sonne D.P., Engstrom T., and Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146 (2008) 243-249
127. Taimor G., Hofstaetter B., and Piper H.M. Apoptosis induction by nitric oxide in adult cardiomyocytes via cGMP-signaling and its impairment after simulated ischemia. Cardiovasc Res 45 (2000) 588-594
128. Cuong D.V., Kim N., Youm J.B., Joo H., Warda M., Lee J.W., et al. Nitric oxide-cGMP-protein kinase G signaling pathway induces anoxic preconditioning through activation of ATP-sensitive K+ channels in rat hearts. Am J Physiol Heart Circ Physiol 290 (2006) H1808-H1817
129. Brunner F., Maier R., Andrew P., Wolkart G., Zechner R., and Mayer B. Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Cardiovasc Res 57 (2003) 55-62
130. D'Souza S.P., Yellon D.M., Martin C., Schulz R., Heusch G., Onody A., et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 284 (2003) H1592-H1600
131. Yang X.M., Philipp S., Downey J.M., and Cohen M.V. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 101 (2006) 311-318
132. Kloner R.A. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 110 (2004) 3149-3155
133. Du Toit E.F., Meiring J., and Opie L.H. Relation of cyclic nucleotide ratios to ischemic and reperfusion injury in nitric oxide-donor treated rat hearts. J Cardiovasc Pharmacol 38 (2001) 529-538
134. Sangawa K., Nakanishi K., Ishino K., Inoue M., Kawada M., and Sano S. Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated rat heart. Ann Thorac Surg 77 (2004) 233-237
135. Golpon H.A., Puechner A., Welte T., Wichert P.V., and Feddersen C.O. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 102 (2001) 81-86
136. Nystrom T., Gonon A.T., Sjoholm A., and Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 125 (2005) 173-177
137. Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 16 (2007) 231-237
138. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24 (2008) 275-286
139. Amori R.E., Lau J., and Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298 (2007) 194-206
140. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 36 (2006) 1696-1705
141. Green B.D., Hand K.V., Dougan J.E., McDonnell B.M., Cassidy R.S., and Grieve D.J. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving K(ATP) and cAMP. Arch Biochem Biophys 478 (2008) 136-142